In the course of anti-tumor therapy,immune encephalitis caused by immune checkpoint inhibitors(ICI)ac-counts for a relatively low proportion of immune-related adverse events(irAE),but once it occurs,it will seriously affect the survival of patients.This article reported a colon cancer patient who was treated with pembrolizumab combined with ipilim-umab and developed neurological symptoms such as slow reaction and slurred speech on the 3rd day of treatment.After a series of examinations,immune encephalitis was considered,and methylprednisolone was administered at a dose of 2 mg·kg-1·d-1.The patient's condition improved after 14 days of treatment,and methylprednisolone was gradually tapered off until it was discontinued.The patient's relevant examination results and symptoms have returned to normal.Early diag-nosis and treatment of immune checkpoint inhibitor-related neurological adverse reactions are of great importance to the prognosis of patients.This report is of great significance for the study of immune encephalitis caused by PD-1 inhibitors and CTLA-4 inhibitors and the design of treatment regimens for this side effect.
国家科技期刊平台
NSTL
万方数据
